News >

Expert Highlights CAR-T and Other Treatment Advances Across Hematologic Malignancies

Caroline Seymour
Published: Tuesday, Jul 02, 2019

Mazyar Shadman, MD, MPH

Mazyar Shadman, MD, MPH
Now that the CD19-targeted CAR T-cell therapies axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah) have shown durable responses in the relapsed/refractory settings of non-Hodgkin lymphoma, researchers are hopeful that earlier exposure may heighten the curative potential of the modality, explained Mazyar Shadman, MD, MPH.

Both constructs are indicated for patients with relapsed/refractory large B-cell lymphoma who have received ≥2 lines of systemic treatment, but a handful of trials are investigating axi-cel and tisagenlecleucel in earlier settings. One such trial is the single-center, phase II ZUMA-12 trial (NCT03761056). In the study, patients with high-risk large B-cell lymphoma will receive a single infusion of axi-cel at a target dose of 2 × 106 CAR T cells/kg.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication